ArticleThe Journal of clinical investigation2012
Epidermal growth factor receptor inhibits colitis-associated cancer in mice.
Article in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 82 citations in OpenAlex.
- Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.Science translational medicine · 2013Trial
- The multifaceted metabolite landscape of gut microbiota: systems pharmacology insights into Crohn's disease, irritable bowel disease, and ulcerative colitis.Molecular diversity · 2026Article
- 2'-Fucosyllactose transactivates EGF receptor in intestinal epithelial cells for prevention of colitis in adulthood.iScience · 2026Article
- Microplastic exposure is associated with enhanced PI3K-Akt signaling in DSS-induced colitis: integrated bioinformatics analyses andFrontiers in pharmacology · 2026Article
- Plasma Proteins Associated with the Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) Diet and Incident Dementia.The Journal of nutrition · 2025Article
- Unique clinical, morphological, and molecular characteristics of tumors associated with PSC-IBD.Virchows Archiv : an international journal of pathology · 2025Review
- Intestinal epithelial PTPN23 is essential for gut barrier integrity and prevention of fatal bacterial translocation.Journal of Crohn's & colitis · 2025Article
- Article
- The miR-7/EGFR axis controls the epithelial cell immunomodulation and regeneration and orchestrates the pathology in inflammatory bowel disease.Journal of advanced research · 2024Article
- Claudin-2 protects against colitis-associated cancer by promoting colitis-associated mucosal healing.The Journal of clinical investigation · 2023Article
- Article
- Computer-Aided Screening and Revealing Action Mechanism of Food-Derived Tripeptides Intervention in Acute Colitis.International journal of molecular sciences · 2022Article
- PDGFA-associated protein 1 is a novel target of c-Myc and contributes to colorectal cancer initiation and progression.Cancer communications (London, England) · 2022Article
- Effects of Spore-Displayed p75 Protein fromMicroorganisms · 2022Article
- Transitional Anal Cells Mediate Colonic Re-epithelialization in Colitis.Gastroenterology · 2022Article
- Interactions between the gut microbiota-derived functional factors and intestinal epithelial cells - implication in the microbiota-host mutualism.Frontiers in immunology · 2022Review
- Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy.Cancers · 2021Article
- Epithelial wound healing in inflammatory bowel diseases: the next therapeutic frontier.Translational research : the journal of laboratory and clinical medicine · 2021Review
- Critical role of interferons in gastrointestinal injury repair.Nature communications · 2021Article
- TNF Receptor 1 Promotes Early-Life Immunity and Protects against Colitis in Mice.Cell reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Inflammatory bowel disease (IBD) is a chronic illness caused by complex interactions between genetic and environmental factors that propagate inflammation and damage to the gastrointestinal epithelium. This state of chronic inflammation increases the risk for development of colitis-associated cancer in IBD patients. Thus, the development of targeted therapeutics that can disrupt the cycle of inflammation and epithelial injury is highly attractive. However, such biological therapies, including those targeting epidermal growth factor receptor pathways, pose a risk of increasing cancer rates. Using two mouse models of colitis-associated cancer, we found that epidermal growth factor receptor inactivation accelerated the incidence and progression of colorectal tumors. By modulating inflammation and epithelial regeneration, epidermal growth factor receptor optimized the response to chronic inflammation and limited subsequent tumorigenesis. These findings provide important insights into the pathogenesis of colitis-associated cancer and suggest that epidermal growth factor-based therapies for IBD may reduce long-term cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.